echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medicines Company News > National Class 1 anti-tumor drug Utidelon was launched

    National Class 1 anti-tumor drug Utidelon was launched

    • Last Update: 2021-07-11
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com


















    Dr.
    Qiu Rongguo, General Manager of Beijing Huahao Zhongtian Biotechnology Co.
    , Ltd.
    said: “Uti Delong is a new generation of broad-spectrum and highly effective anti-cancer drug.
    In addition to the first approved indication for advanced breast cancer, Uti Delong is in the preliminary study.
    It has also shown good anti-tumor activity against a variety of common tumors
    .
    Therefore, as part of continuous innovation, Huahao Zhongtian is carrying out phase II clinical studies for multiple new indications of Utidal injection, involving non-small Cell lung cancer, colorectal cancer, gastrointestinal tumors, gynecological tumors, head and neck tumors and other advanced solid tumor treatments
    .
    At the same time, efforts are being made to promote the development of different dosage forms of Utidel, and it is planned to carry out the oral dosage form of Utidel Sino-US IND double reports, international multi-center clinical development, and promotion of Huahao Zhongtian towards internationalization
    .
    "


    "Huahao Zhongtian's independent key technology platform combines combined biosynthesis technology with unique microbial fermentation technology, focusing on the research and development of natural microbial small molecule anti-tumor innovative drugs
    .
    This technology platform can complete the development of active compounds that are difficult to implement by chemical methods.
    R&D and production give the company the ability to continue to create
    .
    Therefore, we can not only create Utidal, but also develop a series of other drug candidates with different mechanisms of action
    .
    In addition, through a competitive product portfolio, we can carry out combination therapy , And through strategic cooperation with other international and domestic R&D companies to expand the R&D pipeline and R&D fields, the company will gain greater momentum for development
    .
    "


    Mr.
    Zhang Guang, Deputy Director of the Administrative Committee of Beijing Economic and Technological Development Zone, said: “In recent years, Beijing Economic and Technological Development Zone has accelerated the improvement of industrial supporting facilities, created a complete industrial service and policy system, and simultaneously established first-class software and hardware education, Medical facilities and other facilities have gradually developed into a visionary and happy city
    .
    As a member of our Beijing Economic and Technological Development Zone and Yizhuang New Town family, we are happy and excited for the company to achieve such innovative achievements!" 


    Mr.
    Yu Hui, Deputy Secretary of the Party Working Committee and Director of the Management Committee of Chengdu High-tech Zone, said: “The successful listing of UTI Delong is an important achievement made by the demonstration base for the transfer and transformation of major national major scientific and technological achievements in the creation of major new drugs.
    It is also the first in Chengdu High-tech Zone.
    Approved national category 1 original drugs
    .
    Hope that in the future, Chengdu High-tech Zone will further deepen cooperation with experts and companies, and continue to support outstanding corporate investment with a higher level of openness and a better development environment, and jointly compose the development of the biomedical industry.
    A new chapter in the world
    .
    "

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.